tert-butyl 2-amino-4,5,6,7-tetrahydrobenzo[b]thiophene-3-carboxylate | 92932-02-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 噻吩类
• 英文名称: tert-butyl 2-amino-4,5,6,7-tetrahydrobenzo[b]thiophene-3-carboxylate
• 英文别名: 2-Amino-4,5,6,7-tetrahydro-benzo[b]thiophene-3-carboxylic acid tert-butyl ester；tert-butyl 2-amino-4,5,6,7-tetrahydro-1-benzothiophene-3-carboxylate
• CAS: 92932-02-0
• 化学式: C₁₃H₁₉NO₂S
• mdl: MFCD02287893
• 分子量: 253.365
• InChiKey: LBJBSHGWJTXGDG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  17
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.615
• 拓扑面积：
  80.6
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  tert-butyl 2-amino-4,5,6,7-tetrahydrobenzo[b]thiophene-3-carboxylate 在 potassium carbonate 、 calcium carbonate 作用下， 以 二氯甲烷 、 水 、 丙酮 为溶剂， 反应 20.67h， 生成 tert-butyl 2-(3-(4-methylbenzenesulfonyl)thioureido)-4,5,6,7-tetrahydrobenzo[b]thiophene-3-carboxylate
  参考文献：
  名称：

  喹唑啉-4（3 H）-one和类似噻吩并嘧啶-4（3 H）-one的区域选择性磺酰化和N-到O-磺酰基迁移。

  摘要：

  研究了喹唑啉-4（3 H）-酮和相关的四氢苯并噻吩并[2,3 - d ]嘧啶-4（3 H）-与磺酰基，甲苯磺酰基和对氰基苯磺酰氯的磺酰化反应。在2-位的氢取代基将磺酰基引导至N-3位，而烷基硫烷基或氨基取代基导致羰基氧的磺酰化。后者的作用归因于空间影响和2-取代基的正消旋作用。建立了N-磺酰化的2-取代的区域异构体的途径。观察到意外的1，3-磺酰基迁移并进一步分析。此过程发生在分子内N-到O如动力学和交叉实验所证实的-移位。

  DOI：

  10.1021/jo4010876
• 作为产物：
  描述：

  氰乙酸叔丁酯 、 环己烷 在 sulfur 作用下， 以 甲醇 为溶剂， 以72%的产率得到tert-butyl 2-amino-4,5,6,7-tetrahydrobenzo[b]thiophene-3-carboxylate
  参考文献：
  名称：

  Identification of small-molecule inhibitors of USP2a

  摘要：

  USP2a is a deubiquitinating protease that rescues its target proteins from destruction by the proteasome by reversing the process of protein ubiquitination. USP2a shows oncogenic properties in vivo and has been found to be a specific activator of cyclin D1. Many types of cancers are addicted to cyclin D1 expression. Targeting USP2a is a promising strategy for cancer therapy but little progress has been made in the field of inhibition of USP2a. Using NMR-based fragment screening and biophysical binding assays, we have discovered small molecules that bind to USP2a. Iterations of fragment combination and structure-driven design identified two 5-(2-thienyl)-3-isoxazoles as the inhibitors of the USP2a-ubiquitin protein-protein interaction. The affinity of these molecules for the catalytic domain of USP2a parallels their ability to interfere with USP2a binding to ubiquitin in vitro. Altogether, our results establish the 5(2-thienyl)-3-isoxazole pharmacophore as an attractive starting point for lead optimization. (C) 2018 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2018.03.009

文献信息

• [EN] COMPOUNDS FOR TREATING VIRAL INFECTIONS<br/>[FR] COMPOSÉS POUR TRAITER DES INFECTIONS VIRALES
  申请人：PASTEUR INSTITUT KOREA

  公开号：WO2015158908A1

  公开（公告）日：2015-10-22

  The present invention relates to small molecule compounds and their use in the treatment of diseases, in particular viral diseases, in particular hepatitis C virus (HCV).

  本发明涉及小分子化合物及其在治疗疾病中的应用，特别是病毒性疾病，尤其是丙型肝炎病毒（HCV）。
• Fused 1,2,6-Thiadiazines Tetrahydrobenzo[b]thieno[2,3-c] [1,2,6]thiadiazine 2,2-Dioxides
  作者：Pilar Goya、Jaime Lissavetzky、Isabel Rozas、Manfred Stud

  DOI：10.1002/ardp.19843170909

  日期：——

  tetrahydrobenzo[b]thiophene were treated with sulfamoyl chlorides to give sulfamoyl esters and nitriles. Ring closure of these compounds, under various conditions, afforded tetrahydrobenzo[b]thieno[2,3‐c][1,2,6]thiadiazine 2,2‐dioxides. Their herbicidal activities were tested.

  用氨磺酰氯处理四氢苯并[b]噻吩的适当取代衍生物，得到氨磺酰酯和腈。在各种条件下，这些化合物的闭环得到四氢苯并[b]噻吩并[2,3-c][1,2,6]噻二嗪2,2-二氧化物。测试了它们的除草活性。
• Substituted Sulfonamide Compounds
  申请人：MERLA Beatrix

  公开号：US20080312231A1

  公开（公告）日：2008-12-18

  Substituted sulfonamide compounds corresponding to formula I pharmaceutical compositions comprising them, a process for preparing them, and the use of such compounds to treat or inhibit pain and other disorders or disease states.

  将与式I相对应的磺胺化合物替代物 包括它们的药物组合物，制备它们的方法，以及利用这些化合物来治疗或抑制疼痛和其他疾病或疾病状态。
• Design, Synthesis, and Structure–Activity Relationship of <i>N</i>-Aryl-<i>N</i>′-(thiophen-2-yl)thiourea Derivatives as Novel and Specific Human TLR1/2 Agonists for Potential Cancer Immunotherapy
  作者：Zhipeng Chen、Lina Zhang、Junjie Yang、Lu Zheng、Fanjie Hu、Siqin Duan、Kutty Selva Nandakumar、Shuwen Liu、Hang Yin、Kui Cheng

  DOI：10.1021/acs.jmedchem.0c02266

  日期：2021.6.10

  cells. To the best of our knowledge, it is the first species-specific TLR1/2 agonist reported until now. Moreover, SMU-C80 increased the percentage of T, B, and NK cells ex vivo and activated the immune cells, which suppressed cancer cell growth in vitro. In summary, we obtained a highly efficient and specific human TLR1/2 agonist that acts through the MyD88 and NF-κB pathway, facilitating cytokine release

  之前对 1000 万种化合物的虚拟筛选产生了两种新的非脂肽样化学型作为 TLR2 激动剂。在此，我们介绍了我们最初命中的 1-苯基-3-(噻吩-2-基) 脲的化学优化，这导致将 SMU-C80 (EC 50 = 31.02 ± 1.01 nM)鉴定为 TLR2 特异性生物活性提高 370 倍的激动剂。机理研究表明，SMU-C80 通过 TLR1/2 募集接头蛋白 MyD88 并触发 NF-κB 通路以从人类而非鼠类细胞中释放细胞因子，例如 TNF-α 和 IL-1β。据我们所知，它是迄今为止报道的第一个物种特异性 TLR1/2 激动剂。此外，SMU-C80 增加了离体T、B 和 NK 细胞的百分比并激活免疫细胞，从而抑制体外癌细胞的生长。总之，我们获得了一种高效且特异的人 TLR1/2 激动剂，它通过 MyD88 和 NF-κB 途径起作用，促进细胞因子的释放和免疫细胞的同时激活，进而影响癌细胞的凋亡。
• An NMDAR positive and negative allosteric modulator series share a binding site and are interconverted by methyl groups
  作者：Riley Perszyk、Brooke M Katzman、Hirofumi Kusumoto、Steven A Kell、Matthew P Epplin、Yesim A Tahirovic、Rhonda L Moore、David Menaldino、Pieter Burger、Dennis C Liotta、Stephen F Traynelis

  DOI：10.7554/elife.34711

  日期：——

  N-methyl-d-aspartate receptors (NMDARs) are an important receptor in the brain and have been implicated in multiple neurological disorders. Many non-selective NMDAR-targeting drugs are poorly tolerated, leading to efforts to target NMDAR subtypes to improve the therapeutic index. We describe here a series of negative allosteric NMDAR modulators with submaximal inhibition at saturating concentrations. Modest changes to the chemical structure interconvert negative and positive modulation. All modulators share the ability to enhance agonist potency and are use-dependent, requiring the binding of both agonists before modulators act with high potency. Data suggest that these modulators, including both enantiomers, bind to the same site on the receptor and share structural determinants of action. Due to the modulator properties, submaximal negative modulators in this series may spare NMDAR at the synapse, while augmenting the response of NMDAR in extrasynaptic spaces. These modulators could serve as useful tools to probe the role of extrasynaptic NMDARs.

  N-甲基-d-天冬氨酸受体（NMDAR）是大脑中的一种重要受体，与多种神经系统疾病有关。许多非选择性 NMDAR 靶向药物的耐受性都很差，因此人们努力靶向 NMDAR 亚型以提高治疗指数。我们在此介绍了一系列在饱和浓度下具有亚最大抑制作用的负异构 NMDAR 调节剂。化学结构的适度变化可将负调制与正调制相互转换。所有调节剂都具有增强激动剂效力的能力，并且具有使用依赖性，在调节剂发挥高效力之前需要同时与两种激动剂结合。数据表明，这些调节剂（包括两种对映体）与受体上的相同位点结合，并具有共同的作用结构决定因素。由于调制剂的特性，该系列中的亚最大负性调制剂可能会使突触处的 NMDAR 免受影响，同时增强 NMDAR 在突触外空间的反应。这些调节剂可作为探究突触外 NMDAR 作用的有用工具。